LONDON (Reuters) - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study.
The companies, which jointly sell several diabetes drugs, said on Wednesday the so-called SAVOR trial showed that patients on Onglyza had no fewer adverse cardiovascular events, such as heart attacks and strokes, than those on placebo.
Doctors and investors had been awaiting results of the SAVOR trial with keen interest and a positive result could have encouraged increased use of the drug.
In the event, the study found Onglyza was no worse than placebo or standard care in terms of cardiovascular outcomes, but it failed to meet the goal of demonstrating superiority.
(Reporting by Ben Hirschler, Editing by Rosalba O'Brien)
Source: http://news.yahoo.com/astrazeneca-bristol-diabetes-drug-fails-show-heart-benefit-062113731.html
earthquake san francisco donald payne elizabeth berkley lenny dykstra mlb 12 the show sabu franchise tag
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.